RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I FDA Decision: Cabaletta Bio (CABA)

The Phase 2 date for RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I by Cabaletta Bio (CABA) is scheduled for July 1, 2028. This is the target date for the FDA to make a decision on this application.

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I is being developed by Cabaletta Bio for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I receives FDA approval, Cabaletta Bio (CABA) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for CABA on DilutionWatch at dilutionwatch.com/stock/CABA.html.

You can view the full BiotechSigns company profile for Cabaletta Bio (CABA) at biotechsign.com/app/company/CABA, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.